What Orthobond does

Orthobond Corporation is a privately held biotechnology company headquartered in Monmouth Junction, New Jersey, that develops proprietary antimicrobial nanosurface coatings for medical implantable devices. Its core product, Ostaguard™, is a covalent, non-eluting surface treatment less than 100 nanometers thick that uses phosphonate linkers and quaternary ammonium compounds to mechanically rupture pathogens — including bacteria, viruses, and fungi — without antibiotics or eluting chemicals. The technology has demonstrated 99.99% effectiveness against a broad spectrum of pathogens including S. aureus, MRSA, S. epidermidis, P. acnes, P. aeruginosa, E. coli, and C. albicans, and can be applied to existing metallic and polymeric medical devices without requiring design changes.

Orthobond operates a B2B technology licensing model, partnering with medical device manufacturers who integrate Ostaguard into their FDA-cleared products. The company provides end-to-end services including development expertise, regulatory pathway support, and contract manufacturing at its 8,000 square-foot facility, guiding partners from contract completion to FDA submission within approximately 18 months. Named commercial partners include SeaSpine (Mariner Pedicle Screw System for spinal fusion) and Onkos Surgical (oncology/limb salvage implants), both of which received FDA De Novo clearances in April 2024 for Ostaguard-coated products — the first FDA approvals ever granted for a non-eluting antibacterial coating on permanent medical implants.

The company originated from research at Princeton University, was founded around 2009, and has raised approximately $47 million in cumulative funding over 15 years from top-tier angel investors, strategic partners, private grants, and the Kineticos AMR Accelerator Fund I (September 2024). Orthobond identifies broader addressable markets beyond medical devices including textiles, consumer goods, automotive, and high-touch public surfaces. The company operates with 1-10 employees under CEO David Nichols, with Chairman Eric Major (appointed July 2024), Chief Medical Officer Frank P. Cammisa, MD, and Chief Scientific Officer Jordan Katz, Ph.D.

Name

Orthobond

Legal name

Orthobond Corporation

Website

https://orthobond.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Orthobond is a biotechnology company that develops and licenses Ostaguard™, a proprietary non-eluting antibacterial nanosurface coating for medical implantable devices, partnering with medical device manufacturers to integrate antibacterial protection into their FDA-cleared products.

Ownership category

akta.pro rank

Product category

Antimicrobial Medical Device Surface Technology

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Antibacterial surface coatings
• Antimicrobial medical devices
• Implant infection prevention
• Nanosurface technology
• FDA cleared coatings

Headquarters

HQ city

North Brunswick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Technology Licensing to Medical Device Manufacturers: Orthobond licenses its Ostaguard antibacterial coating technology to medical device manufacturers who want to add antibacterial protection to their existing FDA-cleared devices without redesigning them. The company provides development expertise, regulatory support, and manufacturing services.
2. Contract Manufacturing and Application Services: Orthobond applies the Ostaguard coating to partners' devices at their 8,000 square-foot facility in Monmouth Junction, NJ. This includes pre-market testing with established protocol of safety and efficacy tests for FDA-regulated medical devices.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Orthobond develops and licenses Ostaguard™, a proprietary antibacterial nanosurface coating applied to medical implants during manufacturing. The covalent, non-eluting surface treatment mechanically ruptures bacteria, viruses, and fungi on contact without antibiotics or eluting chemicals, and can be permanently bound to metallic and polymeric surfaces. The company partners with medical device manufacturers to apply the coating and provide regulatory and manufacturing support, guiding partners from contract to FDA submission within 18 months.

Product overview

Orthobond is an antimicrobial technology company offering proprietary antibacterial nanosurface technology. Their core product is Ostaguard™, a first-of-its-kind FDA De Novo-approved antibacterial surface coating that mechanically kills pathogens without using antibiotics or eluting chemicals. The technology can be applied to existing medical devices during manufacturing without requiring design changes. Initial applications focus on orthopedic spinal implants, with expansion into trauma, cardiovascular, oncology, plastic surgery, dental, and neuromodulation. The company operates an 8,000 square-foot manufacturing facility and provides regulatory pathway support for device manufacturers seeking FDA clearance for Ostaguard-coated products.

Differentiator

Problem solved

Functional benefit

Brands

• Ostaguard: Proprietary antibacterial surface treatment technology that kills bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics. First FDA De Novo approved non-eluting coating for medical devices with initial application in orthopedic spinal implants.

Products and services

• Ostaguard™ Ostaguard™ is a proprietary antibacterial surface treatment that mechanically kills bacteria, viruses, and fungi on medical implants by rupturing pathogens without using antibiotics. It is the first FDA De Novo-classified non-eluting coating for permanent medical devices, applied during manufacturing prior to packaging and sterilization, and effective at killing 99.99% of bacteria that contact an implantable device. The coating is targeted at medical device manufacturers across orthopedics, spine, trauma, cardiovascular, oncology, dental, plastic surgery, and neuromodulation categories.

Quantifiable outcome

• 99.99% effective in killing multiple strains of bacteria that could come in contact with an implant in the operating room
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, foundational and supporting.

• SeaSpinecoreStrategic or Co-development Partner · 1 April 2024SeaSpine received FDA De Novo clearance for their Mariner Pedicle Screw System with Orthobond's Ostaguard antibacterial coating - the first Ostaguard-coated product to receive FDA approval. SeaSpine manufactures and commercializes the coated pedicle screws for spinal fusion procedures.
• Onkos SurgicalcoreStrategic or Co-development Partner · 1 April 2024Onkos Surgical received separate FDA De Novo approval for orthopedic implants with Orthobond's Ostaguard antibacterial coating for limb salvage procedures. Onkos Surgical developed and manufactures the coated implants and reported the first successful surgeries using the technology.
• MCRAcoreStrategic or Co-development Partner · 1 January 2024MCRA partnered with Orthobond to achieve FDA De Novo clearance for the SeaSpine Mariner Pedicle Screw System with Ostaguard coating. MCRA provided regulatory consulting and clinical expertise for the FDA clearance process.
• Princeton UniversityfoundationalStrategic or Co-development PartnerOrthobond's original platform technology was first developed at Princeton University with the intention of improving the performance of medical devices. The company emerged from over a decade of research, experimentation, collaboration, and persistence originating from this academic partnership.
• Three Prestigious UniversitiessupportingStrategic or Co-development PartnerOrthobond works closely with three prestigious universities in addition to their Princeton origins for ongoing research and development collaboration in chemistry, biomaterials, and microbiology.
• Leading Chemical Industry CompaniessupportingTechnology or IntegrationOrthobond collaborates with the most prominent companies in the chemical industry for raw materials and specialty chemicals needed for their proprietary coating application process.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Covalon Technologies: Canadian company commercializing antimicrobial and biocompatible coatings for medical devices including IV catheters, dressings, and surgical implants. Direct competitor applying surface modification technologies to infection prevention on medical devices.
• BioInteractions: UK-based developer of biocompatible and antimicrobial polymer coatings for medical devices including stents, catheters, and implants. Direct peer in delivering regulatory-cleared surface treatments that prevent device-related infection and thrombosis.
• Sciessent: Provider of antimicrobial technologies (formerly Agion Technologies) for medical devices, healthcare textiles, and consumer products. Direct peer in commercializing silver- and quaternary-ammonium-based antimicrobial surface treatments across healthcare and industrial segments.
• N8 Medical: Specialty company developing antimicrobial coating technologies for medical devices including orthopedic implants and surgical instruments. Direct peer focused on preventing device-related infections through novel surface chemistry — overlapping scientific approach with Ostaguard.
• Hydromer: Developer of hydrogel and antimicrobial coatings for medical devices including catheters, guidewires, and implants. Direct peer applying surface modification technologies licensed to medical device manufacturers for infection prevention.
• AST Products: Provider of surface treatment and coating services for medical devices, including antimicrobial and biocompatible coatings on implants and instruments. Direct peer serving OEM medical device customers with regulatory-cleared surface modification technologies.
• Harland Medical Systems: Provider of surface treatment and coating technologies for medical devices including hydrophilic, antimicrobial, and drug-eluting coatings. Direct peer serving medical device OEMs with contract coating application services analogous to Orthobond's contract manufacturing model.

Broad incumbents

• Surmodics: US-based provider of surface modification coating technologies for in vitro diagnostics, medical devices, and drug delivery. Broad incumbent in medical device coatings with established regulatory and licensing infrastructure that overlaps with Orthobond's OEM partnership model.
• Covestro (formerly DSM Biomedical): Major materials science company (including legacy DSM Biomedical) supplying biocompatible coatings, polymers, and surface treatments for medical devices and implants. Broad incumbent with extensive R&D and global manufacturing footprint relevant to large-scale OEM partnerships.
• Microban International: Global specialty chemical company providing built-in antimicrobial technologies for healthcare, consumer, and industrial products. Broad incumbent with established brand and licensing infrastructure relevant to Orthobond's longer-term consumer/industrial ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/orthobond-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orthobond